Theravance Biopharma (TBPH) Announces Positive Top-Line Four-Week Data from Phase 2 Trial of TD-9855 for the Treatment of Symptomatic Neurogenic Orthostatic Hypotension
Tweet Send to a Friend
Theravance Biopharma, Inc. (NASDAQ: TBPH) today announced positive four-week results from a Phase 2 clinical trial of TD-9855, an investigational ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
